SCHEMBL10078882

SCHEMBL10078882

CC(C)C[C@H](C)NC(=O)[C@@H](C)CCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.65
KMT2A Q03164 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MEN1 O00255 1/20 0.54
HTT P42858 1/20 0.54
HPGD P15428 1/20 0.54
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ANPEP P15144 1/20 0.49
MMP2 P08253 2/20 0.48
MMP3 P08254 2/20 0.48
MMP1 P03956 1/20 0.48
MMP12 P39900 1/20 0.48
MMP13 P45452 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23616381 1.00 TSHR (0.65) TSHRKMT2ASMN1; SMN2MEN1HTT
SCHEMBL11964373 0.86 TSHR (0.67) TSHRKMT2ASMN1; SMN2MEN1HTT
SCHEMBL10060281 0.85 SMN1; SMN2 (0.51) TSHRKMT2ASMN1; SMN2MEN1HTT
SCHEMBL18964688 0.84 TSHR (0.60) TSHRANPEPMMP2MMP3MMP1
SCHEMBL15581362 0.83 ERAP2 (0.64) TSHRANPEPMMP2MMP3MMP1
SCHEMBL21040564 0.83 CPA1 (0.57) TSHRKMT2ASMN1; SMN2MEN1HTT
SCHEMBL17452196 0.82 BIRC2 (0.59) TSHRALDH1A1ANPEPMMP2MMP3
SCHEMBL23616270 0.81 SMN1; SMN2 (0.50) TSHRKMT2ASMN1; SMN2MEN1HTT
SCHEMBL10087282 0.80 MME (0.60) TSHRMMP2MMP3MMP12MMP13
SCHEMBL24437731 0.79 TSHR (0.75) TSHRKMT2ASMN1; SMN2MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163792-B2 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2012-04-24 US disclosed
US-20090192140-A1 IAP BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192140-A1 IAP BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC2, BIRC3 TSHR 3389/4885KMT2A 3594/4885SMN1; SMN2 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.